Epigenetic Targets and Their Inhibitors in Thyroid Cancer Treatment
Pharmaceuticals · 07.04.2023 · 16 (4) · 559
DOI: 10.3390/ph16040559 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 07.04.2023. Verfasst von Ke Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Sha…. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Although biologically targeted therapies based on key oncogenic mutations have made significant progress in the treatment of locally advanced or metastatic thyroid cancer, the challenges of drug resistance are urging us to explore other potentially effective targets. Herein, epigenetic modifications in thyroid cancer, including DNA methylation, histone modifications, non-coding RNAs, chromatin remodeling and RNA alterations, are reviewed and epigenetic therapeutic agents for the treatment of thyroid cancer, such as DNMT (DNA methyltransferase) inhibitors, HDAC (histone deacetylase) inhibitors, BRD4 (bromodomain-containing protein 4) inhibitors, KDM1A (lysine demethylase 1A) inhibitors and EZH2 (enhancer of zeste homolog 2) inhibitors, are updated. We conclude that epigenetics is promising as a therapeutic target in thyroid cancer and further clinical trials are warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Shanghai 200233, China.
- Department of Nuclear Medicine, The First Hospital of Jilin University, 1 Xinmin St., Changchun 130021, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, K., Wang, J., He, Z., Qiu, X., Sa, R., & Chen, L. (2023). Epigenetic Targets and Their Inhibitors in Thyroid Cancer Treatment. Pharmaceuticals, 16(4), 559. https://doi.org/10.3390/ph16040559
Vancouver
Zhang K, Wang J, He Z, Qiu X, Sa R, Chen L. Epigenetic Targets and Their Inhibitors in Thyroid Cancer Treatment. Pharmaceuticals. 2023;16(4):559. doi:10.3390/ph16040559
BibTeX
@article{Zhang2023,
author = {Zhang, Ke and Wang, Junyao and He, Ziyan and Qiu, Xian and Sa, Ri and Chen, Libo},
title = {Epigenetic Targets and Their Inhibitors in Thyroid Cancer Treatment},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {4},
pages = {559},
doi = {10.3390/ph16040559}
}
EUVIMED